AI-native discovery. FDA-cleared pain devices.
Electrome connects scientific evidence, signal modeling, and controlled experiments to investigate new bioelectric therapies through its MATRIX Discovery platform, guided by human scientific review.
Our pain devices are FDA-cleared. Infection and cancer applications are investigational, not cleared or available treatments.
FDA 510(k) cleared (K192234), drug-free wearable for over-the-counter adjunctive treatment of musculoskeletal pain.
Available today: ActiPatch for over-the-counter adjunctive treatment of musculoskeletal pain and prescription RecoveryRx for adjunctive treatment of postoperative pain.
Research directions: infection and cancer. Through AI-native discovery, signal modeling, controlled experiments, and human scientific review, we are exploring future bioelectric applications.
These research directions are not FDA-cleared indications or available treatments. Current device clearances do not extend to infection, cancer, or the research platform.
Our first commercial focus. FDA-cleared PSWT devices: ActiPatch® (K192234) for musculoskeletal pain including plantar fasciitis heel pain, and RecoveryRx® (K190251) for adjunctive treatment of postoperative pain. Over-the-counter ActiPatch® and clinician-directed RecoveryRx® are both developed and manufactured by BioElectronics Corporation.
Pipeline. Exploring bioelectric signaling for neural inflammation, recovery, and cognitive resilience. No commercial product.
Pipeline. PSWT and related modalities are under evaluation for chronic wound and tissue repair indications, building on existing clinical literature.
Commercial. RecoveryRx® is FDA 510(k) cleared (K190251) for adjunctive treatment of postoperative pain. Available through licensed clinicians as part of Electrome's bioelectric therapy offering.
Commercial and platform program connecting FDA-cleared pulsed shortwave therapy with physical therapy, orthopedic, sports medicine, and home recovery workflows. Delivered through clinician-directed RecoveryRx, FDA 510(k) cleared for adjunctive treatment of postoperative pain.
Pipeline and international development initiative exploring wearable bioelectric therapies for pain, inflammation, pelvic health, and recovery. No FDA-cleared U.S. women's health product.
Research. Exploratory evaluation of bioelectric signaling within inflammation pathways, immune signaling environments, and host response biology, including early stage LymeCure preclinical work. Research only, no clinical or regulated product.
Research. Long horizon exploration of bioelectric signaling within tumor microenvironments and cellular electrophysiology, including a planned melanoma research initiative. Research only, no clinical or regulated product.
ActiPatch pairs FDA 510(k) cleared PSWT devices with a clinical workflow. ActiPatch® serves consumers and patients. RecoveryRx®serves providers for postoperative pain and edema.
ActiPatch® and RecoveryRx® are developed and manufactured by BioElectronics Corporation and marketed by Electrome under an exclusive license.
A platform-selected candidate produced a measurable, replicated in-vitro result on the first day of experiments; peer-reviewed publication followed approximately six months after the initial laboratory work. The work was published as Arresting spirochetes: nonthermal extremely low-frequency electromagnetic field exposure suppresses Borrelia burgdorferi motility in vitro.
The complete author group is Erik A. Nilsen, Heather Adkison, John R. Martinez, Nevena Zubcevik, and Monica E. Embers. Dr. Embers's current affiliation is Division of Immunology at the Tulane National Biomedical Research Center, Tulane University.
This preclinical in-vitro result does not establish a Lyme disease treatment, cure, clinical efficacy, or use in people. No Electrome product is cleared or marketed for Lyme disease or any infectious condition. DOI: 10.3389/fmed.2026.1886935.
From selection to publication
Investors, providers, retailers, and researchers. There is a place for you in the Electrome platform.
